NCT07196111View on ClinicalTrials.gov

BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

October 9, 2028

Study Completion Date

December 9, 2028

Conditions

B Acute Lymphoblastic Leukemia/Lymphoma

Interventions

BIOLOGICAL

BAFFR CAR-T

A single infusion of BAFFR CAR-T Injection administered intravenously.

All Listed Sponsors

lead

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY